Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

14-11-2019 | Juvenile idiopathic arthritis | Video | Article

Expert commentary: Safety and efficacy of tofacitinib in juvenile idiopathic arthritis

print
PRINT
insite
SEARCH

Sangeeta Sule gives a pediatric rheumatologist’s view on a trial looking at tofacitinib for the treatment of polyarticular juvenile idiopathic arthritis and the potential implementation of the results in the clinic (2:55).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Transcript

Back to the ACR/ARP 2019 conference hub

print
PRINT

Related content

16-08-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

13-11-2019 | Juvenile idiopathic arthritis | ACR/ARP 2019 | News

Tofacitinib shows efficacy in polyarticular juvenile idiopathic arthritis
Image Credits